Protalix BioTherapeutics to Host Analyst Event in New York City
CARMIEL, Israel, June 12, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE-MKT:PLX) (TASE:PLX), will be hosting an analyst event on Thursday,
June 20, 2013 at 8:00 AM EDT in New York City. The meeting will feature
presentations on ELELYSO®, PRX-102 for the treatment of Fabry disease and Oral
GCD for the treatment of Gaucher disease, as well as presentations on
previously undisclosed product candidates.
Guest speakers include:
- Dr. Gregory Pastores, Associate Professor of Neurology and Pediatrics and
Director of the Neurogenetics Laboratory, The New York University School of
- Vera Wu, Global Asset Lead, Taliglucerase Alfa, Pfizer Inc.
- Dr. Ari Zimran, Associate Professor, Director of the Gaucher Clinic,
Shaare Zedek Medical Center, Jerusalem, Israel
- Dr. Yaron Ilan, Head, Internal Medicine A, Dept. of Medicine and Liver
Unit, Professor, Hadassah Medical Center, Jerusalem, Israel
Company representative speakers include:
- Dr. Einat Almon, Senior Vice President, Product Development, Protalix
- Dr. Yoseph Shaaltiel, Executive Vice President, Research and Development,
- Dr. David Aviezer, President and Chief Executive Officer, Protalix
The analyst event is by invitation only. For information on attending the
event, please contact Marcy Nanus at firstname.lastname@example.org.
The event audio and slide presentation will be webcast live and archived on
the Company's website for a 30-day period. The webcast will be available at
www.protalix.com on the Events Calendar page.The slides will be available
under the presentation tab on the Company's website after the presentation.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell based expression system, ProCellEx®.Protalix's unique
expression system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.Protalix's first
product manufactured by ProCellEx, taliglucerase alfa, was approved for
marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by
Israel's Ministry of Health in September 2012, by the Brazilian National
Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal
Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013,
and by the regulatory authorities of other countries.Marketing applications
for taliglucerase alfa have been filed in additional territories as
well.Protalix has partnered with Pfizer Inc. for the worldwide development
and commercialization of taliglucerase alfa, excluding Israel, where Protalix
retains full rights.Protalix's development pipeline also includes the
following product candidates: PRX-102, a modified version of the recombinant
human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a
pegylated recombinant human acetylcholinesterase in development for several
therapeutic and prophylactic indications, a biodefense program and an
organophosphate-based pesticide treatment program; an orally-delivered
glucocerebrosidase enzyme that is produced and encapsulated within carrot
cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant
cell version of etanercept (Enbrel®) for the treatment of certain immune
diseases such as rheumatoid arthritis, juvenile idiopathic arthritis,
ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.
CONTACT: Investor Contact
The Trout Group, LLC
MacDougall Biomedical Communications
Press spacebar to pause and continue. Press esc to stop.